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Abstract
Background: Neoadjuvant chemotherapy (NACT) is an integral part of multi-modality approach
in the management of locally advanced breast cancer. It is vital to predict response to
chemotherapy in order to tailor the regime for a particular patient. The prediction would help in
avoiding the toxicity induced by an ineffective chemotherapeutic regime in a non-responder and
would also help in the planning of an alternate regime. Development of resistance to
chemotherapeutic agents is a major problem and one of the mechanisms considered responsible is
the expression of 170-k Da membrane glycoprotein (usually referred to as p-170 or p-
glycoprotein), which is encoded by multidrug resistance (MDR1) gene. This glycoprotein acts as an
energy dependent pump, which actively extrudes certain families of chemotherapeutic agents from
the cells. The expression of p-glycoprotein at initial presentation has been found to be associated
with refractoriness to chemotherapy and a poor outcome. Against this background a prospective
study was conducted using C219 mouse monoclonal antibody specific for p-glycoprotein to
ascertain whether pretreatment detection of p-glycoprotein expression could be utilized as a
reliable predictor of response to neoadjuvant chemotherapy in patients with breast cancer.
Patients and methods: Fifty cases of locally advanced breast cancer were subjected to trucut®
biopsy and the tissue samples were evaluated immunohistochemically for p-glycoprotein
expression and ER, PR status. The response to neoadjuvant chemotherapy was assessed clinically
and by using ultrasound after three cycles of FAC regime (cyclophosphamide 600 mg/m2,
Adriamycin 50 mg/m2, 5-fluorourail 600 mg/m2 at an interval of three weeks). The clinical response
was correlated with both the pre and post chemotherapy p-glycoprotein expression. Descriptive
studies were performed with SPSS version 10. The significance of correlation between tumor
response and p-glycoprotein expression was determined with chi square test.
Results: A significant relationship was found between the pretreatment p-glycoprotein expression
and clinical response. The positive p-glycoprotein expression was associated with poor clinical
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response rates. When the clinical response was correlated with p-glycoprotein expression, a
statistically significant negative correlation was observed between the clinical response and p-
glycoprotein expression (p < 0.05). There was another significant observation in terms of
development of post NACT p-glycoprotein positivity. Before initiation of NACT, 26 patients (52%)
were p-glycoprotein positive and after three cycles of NACT, the positivity increased to 73.5%
patients.
Conclusion: The study concluded that pretreatment p-glycoprotein expression predicts and
indicates a poor clinical response to NACT. Patients with positive p-glycoprotein expression
before initiation of NACT were found to be poor responders. Thus pretreatment detection of p-
glycoprotein expression may be utilized, as a reliable predictor of response to NACT in patients
with breast cancer The chemotherapy induced p-glycoprotein positivity observed in the study
could possibly explain the phenomenon of acquired chemoresistance and may also serve as an
intermediate end point in evaluating drug response particularly if the adjuvant therapy is planned
with the same regime.
Background
Neoadjuvant chemotherapy (NACT) is an integral part of
multi-modality approach for the local and systemic man-
agement of locally advanced breast cancer (LABC) [1-5].
However chemoresistance is a major problem and one of
the proposed mechanisms for its development is the
expression of 170-kDa-membrane glycoprotein (usually
referred to as P-170 or P-glycoprotein) encoded by multi
drug resistance-1 (MDR-1) gene [6-9]. This membrane
glycoprotein acts as an energy dependent pump, which
actively inhibits accumulation of certain families of chem-
otherapeutic agents by extruding them from the cells thus
leading to a poor response [8,9].
Immunohistochemical detection using monoclonal anti-
body for p-glycoprotein has been considered to be a more
sensitive method than southern, northern or western blot
analysis because even very low number of positive cells or
lower grade of expression could be readily recognized
[10,11].
In some tumors like leukemia's, multiple myelomas,
Hodgkin's lymphomas, soft tissue sarcomas the expres-
sion of p-glycoprotein at initial presentation has been
found to correlate significantly with refractoriness to
chemotherapy thus highlighting its importance as a con-
tributor to chemoresistance [12,13].
Pretreatment detection of p-glycoprotein has not been
found to be a useful tool for predicting response before
the initiation of chemotherapy in breast cancers as its
expression has not been commonly observed in the
untreated breast cancer cell lines [9,14,15]. There are only
scattered reports in the literature of extraordinarily high
incidence of p-glycoprotein expression in untreated breast
cancer specimen and its role in the assessment of pretreat-
ment p-glycoprotein expression for predicting treatment
failure [15-19].
Against this background a prospective study was con-
ducted using C-219 mouse monoclonal antibody specific
for p-glycoprotein to ascertain whether pretreatment
detection of p-glycoprotein in patients of LABC could be
utilized as a reliable predictor of response to neoadjuvant
chemotherapy.
Patients and methods
After approval by the Institution Review Board and the
ethical committee of the hospital, 50 fine needle aspira-
tion cytology (FNAC) proven cases of LABC according to
AJCC (American Joint Committee on Cancer) classifica-
tion were included in the study. The tumor size and the
axillary lymph node status were measured clinically and
by using ultrasonography. Core biopsy was performed for
immunohistochemical estimations of p-glycoprotein and
ER, PR status in the biopsy specimen before initiating the
chemotherapy. Routine and metastatic work up (total
blood count, platelet count), chest radiograph, electrocar-
diography (ECG) (echocardiography when ECG had a
positive finding), liver function tests, bone scan, ultra-
sonography (USG) of the abdomen, renal function tests
were routinely done in all the cases.
Three cycles of FAC regime (cyclophosphamide 600 mg/
m2, adriamycin 50 mg/m2, 5-fluorourail 600 mg/m2)
were given at three weekly intervals and the patients were
assessed both clinically and by USG for response in the
form of reduction in breast tumor size and axillary lymph
node status. Patey's modified radical mastectomy was per-
formed three weeks after the last cycle and the mastec-
tomy specimen was examined for pathological response,
resected margins, axillary lymph nodes, ER, PR status and
p-glycoprotein expression (post NACT).
The pathological tumor response was evaluated by size
measurement at the time of tumor resectionWorld Journal of Surgical Oncology 2005, 3:61 http://www.wjso.com/content/3/1/61
Page 3 of 9
(page number not for citation purposes)
macroscopically and by detecting tumor cell existence (or
not) microscopically.
Clinical responders were defined as patients with a com-
plete (CR) or partial response (PR) [CR: complete resolu-
tion of tumor, PR>50% regression in maximum diameter
of initial tumor] after 3 cycles of NACT. Non-responders
were patients with a minimal response (MR<50% regres-
sion in maximum diameter of initial tumor), no change
(NC) or local progression. Pathological complete
response (pCR) was defined as absence of any gross or
microscopic evidence of residual tumor in the mastec-
tomy specimen i.e. absence of residual invasive or in situ
disease following NACT. Its assessment was done irrespec-
tive of the clinical response status. Clinical response was
taken in to consideration for statistical analysis as the pCR
was observed in only seven patients (n = 50).
Immunohistochemical methods
Biopsy specimen was preserved in buffered formalin solu-
tion and five-micron sections were prepared on poly-l-
lysine coated glass slides. Sections were deparaffinized in
xylene and hydrated in alcohol for 15 minutes. Further,
incubation was done in 0.3% hydrogen peroxide in meth-
anol solution for 45 minutes; the slides were washed with
citrate buffer and kept in koplin jar with citrate buffer
Positive immunoreactivity for p-glycoprotein in breast carci- noma (200×) Figure 1
Positive immunoreactivity for p-glycoprotein in breast carci-
noma (200×).
Positive immunoreactivity for p-glycoprotein in breast carci- noma (400×) Figure 2
Positive immunoreactivity for p-glycoprotein in breast carci-
noma (400×).
p glycoprotein expression 1+ Figure 3
p glycoprotein expression 1+.
p glycoprotein expression 2+ Figure 4
p glycoprotein expression 2+.World Journal of Surgical Oncology 2005, 3:61 http://www.wjso.com/content/3/1/61
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(pH-6) at 200 power in microwave (5–6 pulses). Sections
were washed with Tris Buffer Saline (TBS) solution and
incubated with blocking antibody (C-219 mouse mono-
clonal antibody) at 37°C overnight. Dilutions used were
1:20. Sections were washed with TBS solution, incubation
done with avidin biotin complex (ABC) at 37°C for one
hour and 3,3 Diaminobezidine tetra hydrochloride solu-
tion was applied for 3–5 minutes. Counter staining with
hematoxylin solution was done for 3–5 minutes. The sec-
tions were washed with distilled water, air-dried and
mounted using DPX mount.
For p-glycoprotein positive, controls were taken as posi-
tive breast cancerous cells and negative controls were
taken as test slides without primary antibody. The pattern
of positive staining was cytoplasmic. The monoclonal
antibody used was C219 antibody (DAKO M3521) [It rec-
ognizes an epitope lying in cytoplasmic domain, 200
amino acids long, of the terminal regions of the p-glyco-
protein polypeptide].
The p-glycoprotein expression was interpreted on the
basis of percentage of p-glycoprotein positive cells against
total population of cells [1+<25%, 2+ = 25–50 % and 3+
>50% positive cells] (figure 1, figure 2, figure 3, figure 4,
figure 5, figure 6, figure 7).
The intensity of staining was also assessed and it was
found that staining intensity correlated closely with per-
centage of positive cells and a single index i.e. percentage
of positive cells was used for analysis.
p glycoprotein expression 3+ Figure 5
p glycoprotein expression 3+.
p glycoprotein expression 3+1 Figure 6
p glycoprotein expression 3+1.
p glycoprotein expression 3+2 Figure 7
p glycoprotein expression 3+2.
Table 1: Tumor size and axillary lymph node status before 
NACT (n = 50)
Tumor size (cm) Frequency Percent
<5 cm 8 16.7
5–8 cm 18[A1] 36.7
8–10 cm 13[A2] 26.7
10 cm 10 20
Lymph node status (N = 50) 100
N1 24 48
N2 26 52World Journal of Surgical Oncology 2005, 3:61 http://www.wjso.com/content/3/1/61
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Statistics
Descriptive studies were performed with SPSS version 10.
The significance of correlation between tumor response
and p-glycoprotein expression was determined with chi
square test.
Results
Fifty cases of LABC were included in the study with the
mean age being 43 years (range 25–60 years) and 26
patients (53.3 %) were premenopausal. The mean tumor
size before NACT was 8 cm. Twenty-four (48%) had N1
disease while 26 patients (52%) presented with N2 dis-
ease in the axilla (table 1).
In the biopsy specimen before initiation of NACT, 26
patients (52%) were p-glycoprotein positive and 24 were
negative (n = 50). The distribution of p-glycoprotein pos-
itive patients based on grades was 1+ and 2+ in 8 patients
each (16%), 3+ in 6(12%) and 4+ in 4(8%) (Additional
file 1). Among the premenopausal patients 16 (59.2%)
stained positive for p-glycoprotein while only 10 (43.4%)
of postmenopausal patients stained positive. The differ-
ence was statistically not significant.
The clinical response was assessed using stringent World
Health Organization (WHO) criteria and reduction in
mean tumor size after three cycles of NACT was found to
be statistically significant (p < 0.05)(table 2). Thirty
patients (n = 50) were responders [complete response in 7
and partial response in 23 patients (n = 30)] while the rest 20
(40%) were non-responders (table 2).
Significant clinical response was observed in the axillary
lymph node status after NACT. There was complete
response in N1 patients (n = 24) i.e. they were all down
staged to N0. Amongst the patients with N2 disease (n =
26), 18(69.2%) were downstaged to N1, the rest
8(31.3%) patients showed no response (table 3). This
downstaging in the axillary lymph node status was found
to be statistically significant (p < 0.05).
The clinical response however did not show have any sig-
nificant correlation with the pre NACT tumor size, age
and menopausal status of the patients. Only seven
patients (14%) showed pCR (pathological response) and
significantly all these were p-glycoprotein negative. There
was no statistically significant correlation observed
between ER status and clinical response in the present
study.
When pre NACT p-glycoprotein expression was correlated
with the clinical response, it was observed that out of 30
clinical responders 21 patients (70%) were p-Glycopro-
tein -ve and 9(30%) were p-glycoprotein +ve while out of
20 clinical non-responders 17 patients were p-glycopro-
tein positive (85%). This was found to be statistically sig-
nificant and as it was observed that most of the non-
responders were p-glycoprotein positive.
Table 2: Mean tumor size before and after NACT (Paired sample statistics)
Status Mean (n) Std.Deviation Std. Error mean
Pre NACT tumor 
size(cm)
8 50 2.7 .50
Post NACT tumor 
size(cm)
4.3 50 2.1 .38
Paired differences t df Significance (2-tailed)
Paired samples test Mean Std. deviation Std. error mean 95% confidence interval of the difference
Pair 1: Pre NACT 
tumor size-Post 
NACT tumor size
3.677 1.6152 .2949 lower 3.074 upper 4.280 12.468 29 0.000
Table 3: Axillary lymph node status before and after NACT(n = 50)
N = 50 N0 N1 N2
Before NACT nil 24(48%) 26(52%)
After NACT 24(48%) 18(36%) 8(16%)World Journal of Surgical Oncology 2005, 3:61 http://www.wjso.com/content/3/1/61
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Significantly all the seven complete responders were p-
glycoprotein negative and out of nine p-glycoprotein pos-
itive patients that were partial responders, six showed very
low levels of p-glycoprotein expression (1+). Thus, there
was a statistically significant correlation observed between
the degree of positivity of p-glycoprotein expression and
poor clinical response (p < 0.05).
When p-glycoprotein positive patients were analyzed for
the grades of positivity and clinical response, it was
observed that increase in grade was associated with
decreased response rates. There was thus an inverse rela-
tion ship observed between p-glycoprotein expression
and the clinical response to NACT.
With an increase in the level of p-glycoprotein expression,
the response rates dropped significantly. When the clini-
cal response was correlated with pre-NACT p-glycoprotein
expression, (With the confidence limit of 99%-p = 0.01,
chi square test was applied) a statistically significant neg-
ative correlation was observed between p-glycoprotein
expression and clinical response
The change in the p-glycoprotein expression before and
after NACT was also found to be statistically significant in
the present study. Before initiation of NACT 26 patients
(52%)were p-glycoprotein positive and after three cycles
of NACT, it increased to 73.5%. This chemotherapy
induced p-glycoprotein positivity could possibly explain
the phenomenon of acquired chemoresistance after NACT
and may also serve as an intermediate end point in
evaluating drug response particularly if the adjuvant ther-
apy is planned with the same regime.
Discussion
Carcinoma of breast is a leading cause of cancer mortality
in women all over the world and the second most com-
mon malignancy in India after carcinoma of the uterine
cervix [1,4]. In India like in other developing countries
25–30% cases are locally advanced at the time of diagno-
sis [1,4]. The recommended approach for the manage-
ment of LABC is a multimodality approach intended to
provide both local and systemic control and studies have
confirmed that surgery alone is an inadequate treatment
[3]. The realization that patients with LABC are likely to
have undetectable micro metastases at diagnosis has lead
to systemic treatment assuming an important role, as even
aggressive surgical techniques do not reduce the higher
incidence of local recurrence. Most importantly surgery
does not change the pattern of distant failure in these
patients as they often have micrometastatic disease at the
time of diagnosis [18-21].
Neoadjuvant chemotherapy was first introduced with a
70% objective response rate in 1970s and was initially uti-
lized to convert unresectable tumors to smaller tumors
making them more amenable to local control with either
surgery or radiotherapy. Although the correlation between
the tumor response and prognosis is still uncertain, it is
generally believed that such a relationship may exist
[2,16,17]. The other important advantage of NACT is that
it provides an in vivo chemosensitivity test for assessment
of tumor response from which prognostic information
could be obtained.
Development of resistance to chemotherapeutic agents is
a major and evolving problem and the search for an ideal
predictor of response is still on [2]. One of the proposed
contributory mechanisms is the expression of p-glycopro-
tein, which is encoded by a family of three genes (MDR1,
MDR2 and MDR3) in rodents and two genes MDR1 (also
known as PGY 1) and MDR 3 (also known on PGY3) in
humans. The MDR 1 and MDR 2 gene products (class 1
and class II isoforms) are involved in drug resistance,
whereas the biological properties of MDR3 gene product
with class II, III isoform are not multidrug resistance [17-
22]. The p-glycoprotein is a 17 Kda membrane glycopro-
tein which functions as an energy dependent drug efflux
pump leading to poor response due to decreased accumu-
lation of drugs inside the cells.
The electrophoretic methods such as Northern and West-
ern blotting in detecting p-glycoprotein expression with
tiny tissue samples containing very small number of p-
glycoprotein expressing tumor cells have not proved satis-
factory. Therefore immunohistochemical detection of p-
glycoprotein using monoclonal antibodies is now widely
accepted for detecting even a single p-glycoprotein
expressing cell or low levels of expression, which could be
missed by electrophoretic analysis [11].
The p-glycoprotein has been reported to be expressed in
several normal human tissues also, notably epithelial cells
with excretory/secretary functions (kidney, liver, colon),
in endothelial cells at several blood tissue barrier sites
(brain, testis), in secretary and gestational endometrium,
in placental trophoblasts, and in adrenal glands (predom-
inantly in the cortex). p-glycoprotein is also expressed in
natural killer cells, lymphocytes, granulocytes, monocytes
and in a minority of CD 34+ hematopoetic stem cells. The
pattern of distribution of p-glycoprotein in normal
humans suggests that its physiological role is to protect
cells against xenobiotics and endogenous toxins [23-25].
Tumors arising in organs that normally express high levels
of p-glycoprotein, such as kidneys, adrenals or colon are
known to be intrinsically resistant to chemotherapy [9]. p-
glycoprotein over expression has also been observed in
leukemia's, cervix cancer as well as in soft tissue sarcomas
[24]. The role of p-glycoprotein in human breast cancer isWorld Journal of Surgical Oncology 2005, 3:61 http://www.wjso.com/content/3/1/61
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however unclear. Most of the published data suggests that
p-glycoprotein expression in primary breast tumor is not
a common phenomenon [23-25].
Sugawara et al detected one positive sample out of nine
tumor samples using MRK-16 monoclonal antibody
(Mab) in a classical immunoperoxidase staining study. In
this study only a few tumor cells were stained within the
positive specimen [14]. Using C219 MAb in an avidin
biotin immunoperoxidase system, Schneider et al, tested
23 breast cancer specimens. None, or only minimal reac-
tivity was found in specimens coming from untreated
patients (12 cases) [9]. Dixon et al, reported no clear pos-
itivity for p-glycoprotein out of 26 primary breast tumors
using 219 Mab [26] and Hyun C et al, used JSB-1 MAb and
detected only 6 p-glycoprotein positive tumors out of
23(26%) primary breast tumors [26]. Verrelle et al,. used
C494 MAb and detected 17 p-glycoprotein positive
tumors out of 20 primary breast tumors. There was a
significant negative correlation observed between p-glyco-
protein expression and clinical response [18]. They had
however used fresh frozen tissue unlike in the present
study where paraffin embedded tissue was used.
Schneider et al, [9] used C 494 and reached exactly oppo-
site results to those observed in the study by Verrelle et al,
[16-18] where the same antibody was used, this could also
be because of the fact that they used fresh frozen tissue
[9,18]. In the present study c219 CoAb antibody was used
and the results obtained were opposite to those of Schnei-
der et al. probably because of the same reasons.
The p-glycoprotein expression in primary breast cancer is
therefore not a commonly observed phenomenon and
only two reports of extraordinarily high incidence of p-
glycoprotein involved in untreated breast cancer speci-
men, have appeared in the recent past [17,18]. Ro et al,
had used 219 Mab and reported that intrinsic drug resist-
ance (pretreatment p-glycoprotein positivity) may play a
role in the failure of induction chemotherapy in locally
advanced breast carcinoma.
In the present study, 26 out of 50 patients were p-glyco-
protein positive (52%) and 30 patients (60%) showed
clinical response to NACT however out of 30 clinical
responders, 21 patients (70%) were p-glycoprotein nega-
tive. It was observed that of the 9 p-glycoprotein positive
patients that were responders, 6 patients showed very low
levels of p-glycoprotein expression (1+). With an increase
in p-glycoprotein expression, the response rate was there-
fore found to drop significantly. The p-glycoprotein posi-
tivity correlated inversely with clinical response to NACT
in the present study.
There are some published reports of a correlation between
p-glycoprotein expression and menopausal status. The
premenopausal patients have been found to have a higher
p-glycoprotein expression than the postmenopausal
patients [26-32]. In the present study however, there was
no statistically significant correlation observed between
the menopausal status and the p-glycoprotein expression.
This discrepancy could have been due to a smaller sample
size.
The presence of estrogen receptors provides a molecular
basis for the distinction between human breast carcinoma
that are responsive to hormone therapy and those that are
not [31]. In various studies correlation between p-glyco-
protein expression and estrogen receptor status has been
found to be unclear [32]. In some studies it was found that
patients whose tumors lacked ER had a higher response
rate to chemotherapy [26-32]. In the present study no sig-
nificant correlation between the ER status and the p-glyo-
protein expression could be found although the sample
size was small and most of the patients were loco region-
ally advanced.
The reported response rates following NACT vary between
49 to 94 % in various studies and this has been due to use
of different chemotherapy combinations given at variable
intervals and doses. The reported pCR rate in most studies
has been 4–34(%)[2]. The largest trial (National Surgical
Adjuvant Breast and Bowel Project NSABP trial B-18)
reported a pCR rate of 13 % [2,33-35]. More recently pCR
rate of 26–34% have been reported with the use of texanes
and the 5-year overall and disease free survival rates were
found to be significantly higher in the group whose
primary tumor had a pCR than in the remaining respond-
ers [2,33-35].
The response rate in our study was 60% while the pCR rate
was 14%(n = 7). The overall clinical response rate
observed was lower than that reported in some published
series (table 4). This could have been due to a smaller
sample size or the fact that majority of our patients were
locoregionally advanced or because of both these factors.
There was a significant clinical response observed in the
axillary lymph node status after NACT in the present study
(table 3). It has also been observed in a recent NSABP B-
18 trial where a significant down staging of the axillary
lymph node status following NACTwas observed [35-37].
In the study of Kuerer et al, conducted at M D Anderson
Cancer Center, on 372 cases of LABC the difference in the
axillary lymph node status before and after NACT was not
found to be statistically significant but a significant corre-
lation has been reported between disease free and overall
survival and the pathological response in the axillary
lymph node status in various studies [2,38].World Journal of Surgical Oncology 2005, 3:61 http://www.wjso.com/content/3/1/61
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There are only few studies reporting an increase in the fre-
quency of p-glycoprotein expression during or after NACT
[15,16]. In the present study it was observed that before
initiation of chemotherapy 26 patients (52%) were p-
glycoprotein positive and after three cycles of NACT,
73.5% patients showed positivity. This increase in fre-
quency of expression after three cycles of NACT could
explain the phenomenon of acquired resistance to chem-
otherapy. The immunohistochemical detection of p-glyc-
oprotein in surgical specimen after NACT would be an
available tool to predict the acquired chemo resistance in
breast carcinoma. It could also be used as an intermediate
end point in determining drug sensitivity for adjuvant
treatment, especially when adjuvant chemotherapy is
planned with the same regimen as NACT.
Conclusion
This study highlights the importance of p-glycoprotein
expression in predicting response to NACT in breast can-
cer patients. Patients with positive p-glycoprotein expres-
sion before initiation of NACT were found to be poor
clinical responders. This pretreatment detection of p-glyc-
oprotein expression may thus be utilized as a predictor of
response to NACT. The increased expression of p-glyco-
protein induced by the NACT probably explains the phe-
nomenon of acquired resistance to chemotherapy and the
detection of post NACT p-glycoprotein can be used as an
intermediate end point in determining drug sensitivity for
adjuvant treatment, especially when adjuvant chemother-
apy is planned with the same regimen as induction chem-
otherapy. The toxic and ineffective chemotherapy may
thus be avoided in non-responders.
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